Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center
Articles
Advice for Community Oncologists on Treating HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Treatments for Relapsed/Refractory HCL in Pipeline
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
The Role of CD22-targeted Immunotoxins in HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Landscape Change in the Treatment of Relapsed/Refractory HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Historical Treatment for Relapsed/Refractory HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Combination First-line Therapy in Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Determining When to Treat and First-Line Therapy for HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Differential Diagnosis and Molecular Tests in Identifying HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Signs and Tests for Diagnosis and Prognosis of HCL
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Molecular Genetic Changes for Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Introduction and Epidemiology of Hairy Cell Leukemia
Steven Coutre, MD, Stanford University Medical Center;Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Alan Saven, MD, Scripps Health;Andrea Sitlinger, MD, Duke University Cancer Institute
June 30th 2020Read More
Latest Updated Articles
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
